APA (7th ed.) Citation

Bryant, J., Sandoval, M., Putney, R., Caslini, C., Katende, E., Fink, A., . . . Grass, D. (2024). Combination of Nivolumab Immunotherapy with Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer: Final Analysis of a Phase 2 Trial. International Journal of Radiation Oncology, Biology, Physics, 120(2), S57. https://doi.org/10.1016/j.ijrobp.2024.07.094

Chicago Style (17th ed.) Citation

Bryant, J.M, et al. "Combination of Nivolumab Immunotherapy with Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer: Final Analysis of a Phase 2 Trial." International Journal of Radiation Oncology, Biology, Physics 120, no. 2 (2024): S57. https://doi.org/10.1016/j.ijrobp.2024.07.094.

MLA (9th ed.) Citation

Bryant, J.M, et al. "Combination of Nivolumab Immunotherapy with Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer: Final Analysis of a Phase 2 Trial." International Journal of Radiation Oncology, Biology, Physics, vol. 120, no. 2, 2024, p. S57, https://doi.org/10.1016/j.ijrobp.2024.07.094.